Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$558.87 USD
+13.41 (2.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $559.71 +0.84 (0.15%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Regeneron Pharmaceuticals, Inc. has a market cap of $58.89B, which represents its share price of $545.46 multiplied by its outstanding shares number of 107.96M. As a large-cap company, REGN's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
REGN 558.87 +13.41(2.46%)
Will REGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nonfarm Payrolls Come in SIgnificantly Below Expectations
Jobs Shrink in the Summer of '25, Pre-Markets Lower
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for REGN
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Regeneron (REGN) Reports Strong Q2 2025 Driven by Key Products
Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Regeneron (REGN) Price Target Cut Amid Eylea Performance Concerns